L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca
23 oct. 2020 01h00 HE
|
INNATE PHARMA
Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
08 oct. 2020 10h30 HE
|
RedHill Biopharma Ltd.
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...
Agility Key to Post-Pandemic Recovery, ISG Experts Say
30 sept. 2020 08h58 HE
|
Information Services Group, Inc.
STAMFORD, Conn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Leading business thinkers will explore the potential of the agile enterprise and digital operating models to drive success in a post-pandemic...
Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222
01 sept. 2020 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
28 mai 2020 07h38 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
BrightInsight Announces Global Digital Health Partnership with AstraZeneca
25 mars 2020 08h00 HE
|
BrightInsight
SAN JOSE, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading regulated Internet of Things (IoT) platform for biopharma and medtech, announced today a global...
New global survey shows misperceptions about lung cancer among the general public
27 nov. 2019 02h00 HE
|
Lung Ambition Alliance
LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Only one in five people (22%) disagree with the statement “generally, patients with lung cancer have caused their illness through their lifestyle choices...
Sabin Vaccine Institute Appoints Filip Dubovsky to Board of Trustees
17 oct. 2019 10h00 HE
|
The Sabin Vaccine Institute
Washington, D.C., Oct. 17, 2019 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that Dr. Filip Dubovsky, head of clinical engagement and policy at AstraZeneca, has joined its...
INNATE PHARMA PRÉSENTE DES RESULTATS CLINIQUES PRELIMINAIRES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019
01 oct. 2019 01h00 HE
|
INNATE PHARMA
Profil de sécurité gérable de la combinaison d’IPH5401 avec durvalumab dans l’étude en escalade de dose STELLAR-001 dans des tumeurs solides avancées Deux extensions de cohorte ont démarré : dans...
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
01 oct. 2019 01h00 HE
|
INNATE PHARMA
IPH5401 dose-escalation study in combination with durvalumab in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer...